US › Healthcare

Telix Pharmaceuticals Limited (TLX)

US · Healthcare · Biotechnology

$12.51+5.71%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$691.4M

Revenue YoY

+265.9%

Net profit

$55.5M

Profit YoY

+375.3%

EPS

$0.04

EPS estimate

$0.08

Net margin

8.0%

EPS came in at 0.04 against a street estimate of 0.08 — a miss of 48.1%.

Key statistics

Market cap

$3.84B

P/E

112.9

Forward P/E

156.2

P/B

7.87

Book value

$1.44

EPS (TTM)

$0.10

52-week high

$12.48

52-week low

$6.28

50-day MA

$11.23

200-day MA

$9.50

Beta

0.60

Analyst view

Analysts rate Telix Pharmaceuticals Limited a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $21.46.

Shareholding

Institutions

0.98%

Largest institutional holders

Fund	Stake
FMR Inc	0.17%
Portolan Capital Management, LLC	0.16%
Lazard Asset Management LLC	0.08%
Manulife AIC Funds	0.08%
Private Advisor Group, LLC	0.06%
Integrated Wealth Concepts LLC	0.05%
Hennion & Walsh Asset Management Inc	0.04%
Raiffeisen Bank International AG	0.04%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Telix Pharmaceuticals Limited — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.